- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07645794
Clinical Study on a New Diagnostic Strategy for Osteoporosis and Sarcopenia in Chronic Kidney Disease Patients Based on MRI-FF
A Clinical Study on Establishing a New Diagnostic Strategy for Osteoporosis and Sarcopenia in Patients With Chronic Kidney Disease Based on MRI-FFR
This is a single-center, observational cohort study aiming to validate the diagnostic value of MRI-FF in identifying osteoporosis and sarcopenia in patients with chronic kidney disease (CKD). A total of 868 participants, including 434 CKD patients and 434 non-CKD controls, will be enrolled at Beijing Jishuitan Hospital. All subjects will undergo MRI-FF scans of the lumbar spine and thigh to assess bone mineral density and muscle fat fraction. The primary objective is to evaluate the correlation between MRI-FF parameters and conventional diagnostic criteria for osteoporosis and sarcopenia, as well as to determine the optimal cut-off values for early detection. The study duration is from March 2026 to December 2028.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studieorter
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100035
- Nephrology Department of Beijing Jishuitan Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
The study population consists of two groups: 434 patients with chronic kidney disease (CKD) and 434 age- and sex-matched healthy controls without CKD. All participants are adults aged 18-80 years old who are able to complete the required MRI scans.
Beskrivning
Inclusion Criteria:
- Age between 18 and 80 years old.
- Able to understand and sign the informed consent form.
- Able to complete MRI-FF scans of the lumbar spine and thigh.
- For CKD group: Confirmed diagnosis of chronic kidney disease (eGFR < 60 mL/min/1.73m² for ≥3 months).
- For control group: No history of chronic kidney disease and normal renal function.
Exclusion Criteria:
- Contraindications to MRI (e.g., pacemaker, metal implants, severe claustrophobia).
- History of primary bone metabolic disorders (e.g., osteoporosis, hyperparathyroidism) unrelated to CKD.
- Current use of anti-osteoporotic drugs (e.g., bisphosphonates, teriparatide).
- Severe lower limb deformity or amputation affecting thigh muscle assessment.
- Inability to cooperate with the scan due to cognitive impairment or severe illness.
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Chronic Kidney Disease (CKD) Group
Patients with chronic kidney disease (CKD) who undergo MRI-FF scans of the lumbar spine and thigh to evaluate bone mineral density and muscle fat fraction. |
MRI fat-fraction (MRI-FF) scan of the lumbar spine and thigh, performed once for all participants to assess bone mineral density and muscle fat fraction. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Correlation between MRI-FF-derived bone mineral density and DXA measurements
Tidsram: At the time of the MRI-FF scan (baseline, one-time assessment)
|
The primary outcome is the correlation coefficient between MRI fat-fraction (MRI-FF) parameters and standard dual-energy X-ray absorptiometry (DXA) bone mineral density values in the lumbar spine of CKD patients and controls. |
At the time of the MRI-FF scan (baseline, one-time assessment)
|
|
Diagnostic performance of MRI-FF for sarcopenia using muscle fat fraction
Tidsram: At the time of the MRI-FF scan (baseline, one-time assessment)
|
The secondary outcome is the diagnostic accuracy (sensitivity, specificity, AUC) of MRI-FF-derived thigh muscle fat fraction in identifying sarcopenia, based on standard diagnostic criteria. |
At the time of the MRI-FF scan (baseline, one-time assessment)
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Dongliang Zhang, MD, Beijing Jishuitan Hospital
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Neurologiska manifestationer
- Skelettsjukdomar
- Muskuloskeletala sjukdomar
- Sjukdomar i nervsystemet
- Neuromuskulära manifestationer
- Patologiska processer
- Manliga urogenitala sjukdomar
- Patologiska tillstånd, anatomiska
- Njursjukdomar
- Urologiska sjukdomar
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Kronisk sjukdom
- Sjukdomsegenskaper
- Metaboliska sjukdomar
- Njurinsufficiens
- Skelettsjukdomar, metaboliska
- Muskelatrofi
- Atrofi
- Patologiska tillstånd, tecken och symtom
- Närings- och metabola sjukdomar
- Tecken och symtom
- Osteoporos
- Sarkopeni
- Njurinsufficiens, kronisk
Andra studie-ID-nummer
- 2026-2-1064
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .